Patents by Inventor Nikola L. Vujanovic

Nikola L. Vujanovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR
    Publication number: 20230285526
    Abstract: Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-? protein and/or a nucleic acid encoding the DN-TNF-? protein. The DN-TNF-? protein and/or a nucleic acid encoding the DN-TNF-? protein can be administered alone or in combination with other agents.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 14, 2023
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nikola L. Vujanovic, Lazar Vujanovic
  • Cancer prevention and therapy by inhibiting soluble tumor necrosis factor
    Patent number: 11633464
    Abstract: Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-? protein and/or a nucleic acid encoding the DN-TNF-? protein. The DN-TNF-? protein and/or a nucleic acid encoding the DN-TNF-? protein can be administered alone or in combination with other agents.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: April 25, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nikola L. Vujanovic, Lazar Vujanovic
  • CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR
    Publication number: 20200093908
    Abstract: Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-? protein and/or a nucleic acid encoding the DN-TNF-? protein. The DN-TNF-? protein and/or a nucleic acid encoding the DN-TNF-? protein can be administered alone or in combination with other agents.
    Type: Application
    Filed: November 19, 2019
    Publication date: March 26, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nikola L. Vujanovic, Lazar Vujanovic
  • Cancer prevention and therapy by inhibiting soluble tumor necrosis factor
    Patent number: 10543264
    Abstract: Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-? protein and/or a nucleic acid encoding the DN-TNF-? protein. The DN-TNF-? protein and/or a nucleic acid encoding the DN-TNF-? protein can be administered alone or in combination with other agents.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: January 28, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nikola L. Vujanovic, Lazar Vujanovic
  • CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR
    Publication number: 20190336591
    Abstract: Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-? protein and/or a nucleic acid encoding the DN-TNF-? protein. The DN-TNF-? protein and/or a nucleic acid encoding the DN-TNF-? protein can be administered alone or in combination with other agents.
    Type: Application
    Filed: December 14, 2016
    Publication date: November 7, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nikola L. Vujanovic, Lazar Vujanovic
  • MICROCYTOXICITY ASSAY BY PRE-LABELING TARGET CELLS
    Publication number: 20080254480
    Abstract: The standard or original microcytotoxicity assay (OMCA) has significant advantages over other cytotoxicity assays, since it is able to detect both cell necrosis and apoptosis and it is simpler, safer, more practical, and more economical. OMCA has serious weaknesses, however, such as low accuracy, low selectivity, and low sensitivity. These drawbacks are ameliorated or eliminated by pre-labeling of target cell nuclei, for instance, with 5-bromo2?-deoxyuridine.
    Type: Application
    Filed: April 11, 2007
    Publication date: October 16, 2008
    Inventor: Nikola L. VUJANOVIC
  • Method for the preparation of pure LAK-active lymphocytes
    Patent number: 5057423
    Abstract: A method for the preparation of LAK-active lymphocytes; a method of immunotherapy utilizing these LAK-active lymphocytes, relatively homogeneous compositions of large granular lymphocytes, and relatively homogeneous compositions of LAK-active lymphocytes.
    Type: Grant
    Filed: December 18, 1987
    Date of Patent: October 15, 1991
    Assignee: University of Pittsburgh
    Inventors: John C. Hiserodt, Nikola L. Vujanovic